Skip to content
Study details
Enrolling now

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

National Institute of Allergy and Infectious Diseases (NIAID)
NCT IDNCT06504160ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

86

Study length

about 1.6 years

Ages

12+

Locations

8 sites in CA, CO, IL +3

About this study

This trial is testing a treatment for atopic dermatitis. It compares ShA9 topical gel to placebo, and also looks at the safety of ShA9 when used with topical corticosteroids.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Clobetasol Ointment
  • 2.Take Fluocinonide Ointment
  • 3.Take Hydrocortisone Ointment
  • +2 more
PhasePhase 1
DrugClobetasol Ointment
Routetopical
Primary goalSerious and non-serious treatment-emergent adverse events (TEAEs) related or possibly related to study treatment

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

clobetasol, CARDIOVASCULAR SYSTEM, hydrocortisone

Drug routes

topical, injection (Injection)

Endpoints

Primary: Serious and non-serious treatment-emergent adverse events (TEAEs) related or possibly related to study treatment.

Secondary: Change in Pruritus Numeric Rating Scale (NRS) score., Serious and non-serious TEAEs related or possibly related to study treatment.

Body systems

Dermatology